Australian (ASX) Stock Market Forum

OSL - Oncosil Medical

Jump to new
adobee

adobee

Joined
29 June 2006
Posts
1,458
Reactions
0
CPS are on the top 20
2 for 1 option listing to raise capital

CPS past asset injections into shell plays -

VOR: Mongolia copper
HUN: mongolia coal
HAR: mongolia IO
 
Re: NDL - NeuroDiscovery

NDL has fallen as people have lost interest in this play and the market overall.. I have started getting options where I can with the little cash I have available ..

Points of interest directors issued themself options expiring Jan 2012
Contracts took options over fees

Doesnt look like I will get the options much cheaper than 1c..
but looks like now is a good with expectation of some action within 6 months
 
Re: NDL - NeuroDiscovery

adobee said:
NDL has fallen as people have lost interest in this play and the market overall.. I have started getting options where I can with the little cash I have available ..

Points of interest directors issued themself options expiring Jan 2012
Contracts took options over fees

Doesnt look like I will get the options much cheaper than 1c..
but looks like now is a good with expectation of some action within 6 months
Click to expand...

some interesting buying from kyle haynes in the past month. bought another 1 % of the company on maket. it will be 2 weeks since his last buy this coming wednesday so Id be expecting some type of announcement within the next month or so. there could be some money looking for a home with great recent returns from ROB, CRJ and VOR
 
Re: NDL - NeuroDiscovery

I have been watching NDL for quite a while, waiting for them (as i suspect) to show their hand for a foray into the resources market.
With 97m shares on issue and $2.2m in the bank NDL is sitting at less than cash value.
With Mattes and O'Loughlin having been brought in, it points to a change of direction, possibly into a 'green' development area.
 
Re: NDL - NeuroDiscovery

Big volume day for NDL, 6.9m traded and up 19%, i'm not saying there is anything stinky going on, but something stinks!

Incredible Charts is not showing it for me atm, so if someone would be kind enough to post a chart that would be appreciated.
 
Re: NDL - NeuroDiscovery

springhill said:
Big volume day for NDL, 6.9m traded and up 19%, i'm not saying there is anything stinky going on, but something stinks!

Incredible Charts is not showing it for me atm, so if someone would be kind enough to post a chart that would be appreciated.
Click to expand...

Director bought 100,000 for $2,000!
 

Attachments

  • ndl.gif
    ndl.gif
    17.2 KB · Views: 4
Re: NDL - NeuroDiscovery

Course Of Sales
Time Price ($) Volume Value ($)
3:38:35 PM 0.025 2,500,000 62,500.00
3:38:32 PM 0.025 4,323,530 108,088.25
3:34:44 PM 0.024 78,401 1,881.62



Sorry about the table being wonkey!!


Maybe the directors bought more today!

Time will tell!
 
Re: NDL - NeuroDiscovery

burglar said:
Course Of Sales
Time Price ($) Volume Value ($)
3:38:35 PM 0.025 2,500,000 62,500.00
3:38:32 PM 0.025 4,323,530 108,088.25
3:34:44 PM 0.024 78,401 1,881.62



Sorry about the table being wonkey!!
Maybe the directors bought more today!
Time will tell!
Click to expand...

Directors have been buying, off market and a small amount on market.
http://www.asx.com.au/asxpdf/20120622/pdf/426zvmzfxfm3v8.pdf
http://www.asx.com.au/asxpdf/20120626/pdf/4271j6s184dntg.pdf

Another off market trade announced today.
http://www.asx.com.au/asxpdf/20120627/pdf/42722vrqpjcnh7.pdf
 
On June 3rd, 2013, NeuroDiscovery Limited (NDL) changed its name to Oncosil Medical Limited (OSL).
 
System said:
On June 3rd, 2013, NeuroDiscovery Limited (NDL) changed its name to Oncosil Medical Limited (OSL).
Click to expand...
Very interesting treatment for pancreatic cancer, delivering radioactive particles directly to the tumour, early indications are that it has a longer survival rate than the current treatment, meetings being held in Perth with some of St Georges terraces more respected movers and shakers.
Credit raising is however inevitable, the question is at what price?
Can anybody post any more information, or links?
Finding it hard to research outside of Oncosils own info.
Going on the success of similar delivery systems originating out of Perth, and the track record of the board, this one is well worth having a look at.
Would appreciate anyone with a deeper knowledge of the company/technology posting an opinion.
Thanks
Jewels :D
 
latest ASX announcement:
Is there anyone else out there????
ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL
Suite 1802, Level 18, 15 Castlereagh Street Sydney NSW 2000 AUSTRALIA
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9221 8535
WEB www.oncosil.com.au
ASX / Media Release
OncoSil Medical initiates US FDA gap analysis
● The path to initiate a pivotal clinical trial in pancreatic cancer patients will be determined by this analysis
● OncoSil™, the company’s product in development, has the potential to fill a major unmet medical need in pancreatic cancer
● There are highly successful commercialised precedents for Investigational Device Exemption (IDE) for localised radiation treatments for hepatic and prostate cancer
● The IDE, if approved, will allow OncoSil Medical to recruit patients into the pivotal pancreatic cancer study in the US
● The gap analysis will review all OncoSil Medical’s data generated to date on the manufacture of the OncoSil™ device to establish the regulatory path for the pre-IDE meeting
SYDNEY, 8th August, 2013 : OncoSil Medical Limited (ASX: OSL) is pleased to announce the following update on an advance in the development of its product candidate, OncoSil™. The company is initiating a gap analysis assessment of OncoSil™, which is an important step in defining the regulatory pathway to a pre Investigation Device Exemption (IDE) meeting with the US Food and Drug Administration (FDA).
Pancreatic cancer is a devastating disease and treatment of this cancer remains a challenge. OncoSil Medical believes that new implantable radiotherapies such as OncoSil™ may have the opportunity to treat the disease and the debilitating pain associated with it. The United States has over 40,000 patients diagnosed annually with pancreatic cancer, and is the largest single market for healthcare in the world. Treatment of pancreatic cancer remains a major unmet medical need, as the median survival after diagnosis is only 5 months. Surgery is only feasible in 20% of patients, and chemotherapeutic treatments only work in around 15% of patients. Radiation therapy is used, but has systemic side effects in an already sick patient population. Localised radiation therapy supplied by OncoSil™ offers a potential treatment without systemic side effects.
OncoSil Medical is developing OncoSil™ as an implantable device that emits radiation directly into the pancreatic tumour, and the pain conducting nerves surrounding it. Radiation therapy, such as that supplied by OncoSil™ is known to kill tumour cells, and OncoSil™ delivers radiation therapy locally for up to three
ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL
Suite 1802, Level 18, 15 Castlereagh Street Sydney NSW 2000 AUSTRALIA
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9221 8535
WEB www.oncosil.com.au
months. The device is inserted directly into the centre of the tumour using well established technology in a short 15-30 minute procedure.
OncoSil Medical has engaged regulatory consultancy Emergo Group as experts to support a US FDA IDE submission. The firm has extensive experience in supporting medical device submissions globally, and particularly in the US. In order to ensure an optimal submission, Emergo Group will compile an FDA Regulatory Pathway report, taking into account the company’s current data for OncoSil™.
The IDE involves submission of manufacturing data, a protocol, an investigators brochure and any clinical safety and efficacy data generated to date, to permit the pivotal clinical study to be conducted in the US. As part of the FDA Regulatory Pathway report, OncoSil Medical and Emergo Group will determine if a simple reference device comparison approach (a 510(k) submission) or a Pre Marketing Authorisation (PMA) is appropriate.
The global pivotal clinical study predicted to commence next year is being designed to provide data on the safety and efficacy of the device, in a randomized and controlled fashion. If positive, the data generated by the clinical study will facilitate commercialization of OncoSil™.
Commenting on the strategic approach, Dr. Neil Frazer, CEO of OncoSil Medical noted “a gap analysis, and the initiation of the pathway to an IDE, will stand us in excellent stead as we move OncoSil™ through the regulatory processes required to support commercialization of the product. We welcome our relationship with Emergo Group, a well-established consulting organization with expertise in medical device regulatory compliance, to conduct the analysis and support our application for an IDE.”
Emergo Group is also providing expert support for the regulatory process around submission and potential commercialization of OncoSil™ in Europe.
ENDS
Contact:
Dr Neil Frazer
Chief Executive Officer and Managing Director
neil.frazer@oncosil.com.au
T +61 2 9223 3344
Twitter: @Dr_Neil_Frazer

I hope this will spark some interest.
Some interesting points:
This is a medical device, and not a drug, as such FDA approval should be easier and faster than a new drug.
Tests done to date, admittedly on a very small sample, suggest that survival rate is approx double the current gold standard treatment.
Treatment is currently for Pancreatic CA. There is no reason why the same technique could not be used in other radiation sensitive cancers in other locations where a scope can get you to close proximity. (Think Sirts for pancreatic cancer).
Have a close look at this one.
The only question is how much money do we need for the trials, and more importantly the navigation of the red tape leading up to the approval of the trials, and when will it need to be raised?
Anybody with expertise in this area who could give me any idea as to how much we need, I would love your input.
Thanks Jewels:D
 
Jewels said:
latest ASX announcement:
Is there anyone else out there????

I hope this will spark some interest.
Some interesting points:
This is a medical device, and not a drug, as such FDA approval should be easier and faster than a new drug.
Tests done to date, admittedly on a very small sample, suggest that survival rate is approx double the current gold standard treatment.
Treatment is currently for Pancreatic CA. There is no reason why the same technique could not be used in other radiation sensitive cancers in other locations where a scope can get you to close proximity. (Think Sirts for pancreatic cancer).
Have a close look at this one.
The only question is how much money do we need for the trials, and more importantly the navigation of the red tape leading up to the approval of the trials, and when will it need to be raised?
Anybody with expertise in this area who could give me any idea as to how much we need, I would love your input.
Thanks Jewels:D
Click to expand...

Jewels, I noticed OSL from a charts perspective first then read up on what they are trying to achieve. It looks interesting and the upside is obviously huge - may be a SRX 2.0 in 5 years time.

But without being an expert in the field it is impossible for me to judge what is their chance of success, or their people's credentials to bring it to bear... and the capital required as you've already mentioned. There aren't even much analyst reports (some perhaps more trustworthy than others) out there to help make such decisions.

So there are few viable options for a potential investor:

1. Self-teach to become an expert in the field.
2. Take a small faith-based punt while keeping risk in check.
3. Wait for strong evidence of their products viability and commercialisation.
4. Trade it technically.
5. Put in the too hard basket.

Which option are you subscribing to? Or something different altogether?
 
Firstly my previous post should have read Sirts for prostate cancer and not pancreatic cancer, my apologies.
Thanks for replying SKC, at least I know one other person has read my posts!
I took a small position a couple of weeks ago, sub 5 cents, now the market cap has doubled to 22 million dollars, so I'm doing ok at the moment. I wanted to put in a whole lot more, but just couldn't find a broker with knowledge, or an interventional radiologist who is aware of the system/technology. So decided to just "stick a toe in the water"
I think I'll drop an email to Oncosil and see if I can get any answers re the existing trial, and any idea at all what the time frame is and the process required from the US regulators.
From my very limited knowledge, it's not a matter of "if" this technology is used, but when, and if it will be developed by Oncosil or something similar developed by somebody else.
I'll ask if they mind me posting the reply to the email.
At this stage I can't see anyway that Oncosil will be able to bring this technology to market, however it would be a doddle for a Philips, Toshiba, GE etc to include with their endoscopic ultrasound products, so I envisage a takeover as soon as the technology has the required permits/licenses...
So if anyone else can give me some info, or guide me as to where to look I would appreciate the heads up.
Stay Tuned.........
 
Well the market appears to like what it hears with a nearly 30% rise in the stock over the past couple of days. Today's volume was nearly 4 million - the largest for several weeks.
 

Similar threads

R
The Financial Endgame
Replies
18
Views
9K
qldfrog
qldfrog
Top